{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:27:12Z","timestamp":1791563232895,"version":"4.3.4"},"reference-count":130,"publisher":"Japan Academy","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Proc. Jpn. Acad., Ser. B","Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences"],"published-print":{"date-parts":[[2020,6,11]]},"DOI":"10.2183\/pjab.96.016","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T22:05:44Z","timestamp":1591826744000},"page":"189-203","source":"Crossref","is-referenced-by-count":120,"title":["Molecular mechanisms of thalidomide and its derivatives"],"prefix":"10.2183","volume":"96","author":[{"given":"Takumi","family":"ITO","sequence":"first","affiliation":[{"name":"Department of Chemical Biology, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"HANDA","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"993","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) McBride, W.G. (1977) Thalidomide embryopathy. Teratology <b>16<\/b>, 79\u201382.","DOI":"10.1002\/tera.1420160113"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Franks, M.E., Macpherson, G.R. and Figg, W.D. (2004) Thalidomide. Lancet <b>363<\/b>, 1802\u20131811.","DOI":"10.1016\/S0140-6736(04)16308-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Melchert, M. and List, A. (2007) The thalidomide saga. Int. J. Biochem. Cell Biol. <b>39<\/b>, 1489\u20131499.","DOI":"10.1016\/j.biocel.2007.01.022"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sheskin, J. (1965) Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. <b>6<\/b>, 303\u2013306.","DOI":"10.1002\/cpt196563303"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gutierrez-Rodriguez, O. (1984) Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. <b>27<\/b>, 1118\u20131121.7.","DOI":"10.1002\/art.1780271006"},{"key":"6","unstructured":"6) Vogelsang, G.B., Hess, A.D. and Santos, G.W. (1988) Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant. <b>3<\/b>, 393\u2013398."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Vogelsang, G.B., Farmer, E.R., Hess, A.D., Altamonte, V., Beschorner, W.E., Jabs, D.A.  (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. <b>326<\/b>, 1055\u20131058.","DOI":"10.1056\/NEJM199204163261604"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. <b>173<\/b>, 699\u2013703.","DOI":"10.1084\/jem.173.3.699"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A. and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. <b>177<\/b>, 1675\u20131680.","DOI":"10.1084\/jem.177.6.1675"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) D\u2019Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. <b>91<\/b>, 4082\u20134085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P.  (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. <b>341<\/b>, 1565\u20131571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"12","unstructured":"12) Zeldis, J.B., Williams, B.A., Thomas, S.D. and Elsayed, M.E. (1999) S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. <b>21<\/b>, 319\u2013330."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ooba, N., Sato, T., Watanabe, H. and Kubota, K. (2010) Resolving a double standard for risk management of thalidomide: An evaluation of two different risk management programmes in Japan. Drug Saf. <b>33<\/b>, 35\u201345.","DOI":"10.2165\/11318920-000000000-00000"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Muller, G.W., Chen, R., Huang, S.Y., Corral, L.G., Wong, L.M., Patterson, R.T.  (1999) Amino-substituted thalidomide analogs: Potent inhibitors of TNF-\u03b1 production. Bioorg. Med. Chem. Lett. <b>9<\/b>, 1625\u20131630.","DOI":"10.1016\/S0960-894X(99)00250-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Bartlett, J.B., Dredge, K. and Dalgleish, A.G. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer <b>4<\/b>, 314\u2013322.","DOI":"10.1038\/nrc1323"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D.  (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. <b>352<\/b>, 549\u2013557.","DOI":"10.1056\/NEJMoa041668"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E.  (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. <b>355<\/b>, 1456\u20131465.","DOI":"10.1056\/NEJMoa061292"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A.  (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. <b>357<\/b>, 2123\u20132132.","DOI":"10.1056\/NEJMoa070594"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Habermann, T.M., Lossos, I.S., Justice, G., Vose, J.M., Wiernik, P.H., McBride, K.  (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. <b>145<\/b>, 344\u2013349.","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ruan, J., Martin, P., Shah, B., Schuster, S.J., Smith, S.M., Furman, R.R.  (2015) Lenalidomide plus Rituximab as initial treatment for mantle-cell lymphoma. N. Engl. J. Med. <b>373<\/b>, 1835\u20131844.","DOI":"10.1056\/NEJMoa1505237"},{"key":"21","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","author":"A.G. Ramsay","year":"2009","unstructured":"21) Ramsay, A.G., Clear, A.J., Kelly, G., Fatah, R., Matthews, J., Macdougall, F.  (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: Implications for the tumor microenvironment and immunotherapy. Blood <b>114<\/b>, 4713\u20134720.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Morschhauser, F., Fowler, N.H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M.L.  (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N. Engl. J. Med. <b>379<\/b>, 934\u2013947.","DOI":"10.1056\/NEJMoa1805104"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Shimizu, N., Sugimoto, K., Tang, J., Nishi, T., Sato, I., Hiramoto, M.  (2000) High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. <b>18<\/b>, 877\u2013881.","DOI":"10.1038\/78496"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nishio, K., Masaike, Y., Ikeda, M., Narimatsu, H., Gokon, N., Tsubouchi, S.  (2008) Development of novel magnetic nano-carriers for high-performance affinity purification. Colloids Surf. B Biointerfaces <b>64<\/b>, 162\u2013169.","DOI":"10.1016\/j.colsurfb.2008.01.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y.  (2010) Identification of a primary target of thalidomide teratogenicity. Science <b>327<\/b>, 1345\u20131350.","DOI":"10.1126\/science.1177319"},{"key":"26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature14628","author":"T. Ito","year":"2015","unstructured":"26) Ito, T. and Handa, H. (2015) Myeloid disease: Another action of a thalidomide derivative. Nature <b>523<\/b>, 167\u2013168.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Asatsuma-Okumura, T., Ito, T. and Handa, H. (2019) Molecular mechanisms of cereblon-based drugs. Pharmacol. Ther. <b>202<\/b>, 132\u2013139.","DOI":"10.1016\/j.pharmthera.2019.06.004"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Petroski, M.D. and Deshaies, R.J. (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. <b>6<\/b>, 9\u201320.","DOI":"10.1038\/nrm1547"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Angers, S., Li, T., Yi, X., MacCoss, M.J., Moon, R.T. and Zheng, N. (2006) Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature <b>443<\/b>, 590\u2013593.","DOI":"10.1038\/nature05175"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Chamberlain, P.P. and Cathers, B.E. (2019) Cereblon modulators: Low molecular weight inducers of protein degradation. Drug Discov. Today Technol. <b>31<\/b>, 29\u201334.","DOI":"10.1016\/j.ddtec.2019.02.004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Deshaies, R.J. (2015) Protein degradation: Prime time for PROTACs. Nat. Chem. Biol. <b>11<\/b>, 634\u2013635.","DOI":"10.1038\/nchembio.1887"},{"key":"32","unstructured":"32) Lai, A.C. and Crews, C.M. (2016) Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. <b>16<\/b>, 101\u2013114."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kubota, K., Funabashi, M. and Ogura, Y. (2019) Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches. Biochim. Biophys. Acta Proteins Proteom. <b>1867<\/b>, 22\u201327.","DOI":"10.1016\/j.bbapap.2018.08.002"},{"key":"34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1126\/science.3529394","author":"M.R. Briggs","year":"1986","unstructured":"34) Briggs, M.R., Kadonaga, J.T., Bell, S.P. and Tjian, R. (1986) Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science <b>234<\/b>, 47\u201352.","journal-title":"Science","ISSN":"https:\/\/id.crossref.org\/issn\/0036-8075","issn-type":"print"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Uga, H., Kuramori, C., Ohta, A., Tsuboi, Y., Tanaka, H., Hatakeyama, M.  (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol. Pharmacol. <b>70<\/b>, 1832\u20131839.","DOI":"10.1124\/mol.106.025866"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kabe, Y., Ohmori, M., Shinouchi, K., Tsuboi, Y., Hirao, S., Azuma, M.  (2006) Porphyrin accumulation in mitochondria is mediated by 2-oxoglutarate carrier. J. Biol. Chem. <b>281<\/b>, 31729\u201331735.","DOI":"10.1074\/jbc.M604729200"},{"key":"37","unstructured":"37) Iizumi, Y., Sagara, H., Kabe, Y., Azuma, M., Kume, K., Ogawa, M.  (2007) The enteropathogenic <i>E. coli<\/i> effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function. Cell Host Microbe <b>2<\/b>, 383\u2013392."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yoshida, M., Kabe, Y., Wada, T., Asai, A. and Handa, H. (2008) A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol. Pharmacol. <b>73<\/b>, 987\u2013994.","DOI":"10.1124\/mol.107.043307"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Azuma, M., Kabe, Y., Kuramori, C., Kondo, M., Yamaguchi, Y. and Handa, H. (2008) Adenine nucleotide translocator transports haem precursors into mitochondria. PLoS One <b>3<\/b>, e3070.","DOI":"10.1371\/journal.pone.0003070"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kuramori, C., Hase, Y., Hoshikawa, K., Watanabe, K., Nishi, T., Hishiki, T.  (2009) Mono-(2-ethylhexyl) phthalate targets glycogen debranching enzyme and affects glycogen metabolism in rat testis. Toxicol. Sci. <b>109<\/b>, 143\u2013151.","DOI":"10.1093\/toxsci\/kfp041"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Kume, K., Iizumi, Y., Shimada, M., Ito, Y., Kishi, T., Yamaguchi, Y.  (2010) Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the leucine-mTOR signaling pathway. Genes Cells <b>15<\/b>, 339\u2013349.","DOI":"10.1111\/j.1365-2443.2010.01385.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ito, Y., Ito, T., Karasawa, S., Enomoto, T., Nashimoto, A., Hase, Y.  (2012) Identification of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel target of bisphenol A. PLoS One <b>7<\/b>, e50481.","DOI":"10.1371\/journal.pone.0050481"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Sakamoto, S., Hatakeyama, M., Ito, T. and Handa, H. (2012) Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound. Bioorg. Med. Chem. <b>20<\/b>, 1990\u20132001.","DOI":"10.1016\/j.bmc.2011.12.022"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Karasawa, S., Azuma, M., Kasama, T., Sakamoto, S., Kabe, Y., Imai, T.  (2013) Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis. Mol. Pharmacol. <b>83<\/b>, 613\u2013620.","DOI":"10.1124\/mol.112.082602"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Kabe, Y., Nakane, T., Koike, I., Yamamoto, T., Sugiura, Y., Harada, E.  (2016) Haem-dependent dimerization of PGRMC1\/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat. Commun. <b>7<\/b>, 11030.","DOI":"10.1038\/ncomms11030"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Higgins, J.J., Pucilowska, J., Lombardi, R.Q. and Rooney, J.P. (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology <b>63<\/b>, 1927\u20131931.","DOI":"10.1212\/01.WNL.0000146196.01316.A2"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Wittschieben, B.O. and Wood, R.D. (2003) DDB complexities. DNA Repair (Amst.) <b>2<\/b>, 1065\u20131069.","DOI":"10.1016\/S1568-7864(03)00113-7"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Iovine, B., Iannella, M.L. and Bevilacqua, M.A. (2011) Damage-specific DNA binding protein 1 (DDB1): A protein with a wide range of functions. Int. J. Biochem. Cell Biol. <b>43<\/b>, 1664\u20131667.","DOI":"10.1016\/j.biocel.2011.09.001"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49) Pickart, C.M. (2004) Back to the future with ubiquitin. Cell <b>116<\/b>, 181\u2013190.","DOI":"10.1016\/S0092-8674(03)01074-2"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Hotton, S.K. and Callis, J. (2008) Regulation of cullin RING ligases. Annu. Rev. Plant Biol. <b>59<\/b>, 467\u2013489.","DOI":"10.1146\/annurev.arplant.58.032806.104011"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Lee, J. and Zhou, P. (2007) DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell <b>26<\/b>, 775\u2013780.","DOI":"10.1016\/j.molcel.2007.06.001"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52) Sugasawa, K., Okuda, Y., Saijo, M., Nishi, R., Matsuda, N., Chu, G.  (2005) UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell <b>121<\/b>, 387\u2013400.","DOI":"10.1016\/j.cell.2005.02.035"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Jin, J., Arias, E.E., Chen, J., Harper, J.W. and Walter, J.C. (2006) A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell <b>23<\/b>, 709\u2013721.","DOI":"10.1016\/j.molcel.2006.08.010"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54) Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J., Saijo, M., Drapkin, R.  (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell <b>113<\/b>, 357\u2013367.","DOI":"10.1016\/S0092-8674(03)00316-7"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Lieschke, G.J. and Currie, P.D. (2007) Animal models of human disease: Zebrafish swim into view. Nat. Rev. Genet. <b>8<\/b>, 353\u2013367.","DOI":"10.1038\/nrg2091"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Lewandoski, M., Sun, X. and Martin, G.R. (2000) Fgf8 signalling from the AER is essential for normal limb development. Nat. Genet. <b>26<\/b>, 460\u2013463.","DOI":"10.1038\/82609"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Moon, A.M. and Capecchi, M.R. (2000) Fgf8 is required for outgrowth and patterning of the limbs. Nat. Genet. <b>26<\/b>, 455\u2013459.","DOI":"10.1038\/82601"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Hansen, J.M., Gong, S.G., Philbert, M. and Harris, C. (2002) Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev. Dyn. <b>225<\/b>, 186\u2013194.","DOI":"10.1002\/dvdy.10150"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Lopez-Girona, A., Heintel, D., Zhang, L.H., Mendy, D., Gaidarova, S., Brady, H.  (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br. J. Haematol. <b>154<\/b>, 325\u2013336.","DOI":"10.1111\/j.1365-2141.2011.08689.x"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60) Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S.  (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood <b>118<\/b>, 4771\u20134779.","DOI":"10.1182\/blood-2011-05-356063"},{"key":"61","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","author":"A. Lopez-Girona","year":"2012","unstructured":"61) Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J.  (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia <b>26<\/b>, 2326\u20132335.","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Kronke, J., Udeshi, N.D., Narla, A., Grauman, P., Hurst, S.N., McConkey, M.  (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science <b>343<\/b>, 301\u2013305.","DOI":"10.1126\/science.1244851"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Lu, G., Middleton, R.E., Sun, H., Naniong, M., Ott, C.J., Mitsiades, C.S.  (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science <b>343<\/b>, 305\u2013309.","DOI":"10.1126\/science.1244917"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L.  (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4<sup>CRBN<\/sup>. Br. J. Haematol. <b>164<\/b>, 811\u2013821.","DOI":"10.1111\/bjh.12708"},{"key":"65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","author":"J. Kronke","year":"2015","unstructured":"65) Kronke, J., Fink, E.C., Hollenbach, P.W., MacBeth, K.J., Hurst, S.N., Udeshi, N.D.  (2015) Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature <b>523<\/b>, 183\u2013188.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","author":"M.E. Matyskiela","year":"2016","unstructured":"66) Matyskiela, M.E., Lu, G., Ito, T., Pagarigan, B., Lu, C.C., Miller, K.  (2016) A novel cereblon modulator recruits GSPT1 to the CRL4<sup>CRBN<\/sup> ubiquitin ligase. Nature <b>535<\/b>, 252\u2013257.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Cheng, Z., Saito, K., Pisarev, A.V., Wada, M., Pisareva, V.P., Pestova, T.V.  (2009) Structural insights into eRF3 and stop codon recognition by eRF1. Genes Dev. <b>23<\/b>, 1106\u20131118.","DOI":"10.1101\/gad.1770109"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Kikuchi, Y., Shimatake, H. and Kikuchi, A. (1988) A yeast gene required for the G1-to-S transition encodes a protein containing an A-kinase target site and GTPase domain. EMBO J. <b>7<\/b>, 1175\u20131182.","DOI":"10.1002\/j.1460-2075.1988.tb02928.x"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Chamberlain, P.P. and Hamann, L.G. (2019) Development of targeted protein degradation therapeutics. Nat. Chem. Biol. <b>15<\/b>, 937\u2013944.","DOI":"10.1038\/s41589-019-0362-y"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Hansen, J.D., Condroski, K., Correa, M., Muller, G., Man, H.W., Ruchelman, A.  (2018) Protein degradation via CRL4<sup>CRBN<\/sup> ubiquitin ligase: Discovery and structure-activity relationships of novel glutarimide analogs that promote degradation of Aiolos and\/or GSPT1. J. Med. Chem. <b>61<\/b>, 492\u2013503.","DOI":"10.1021\/acs.jmedchem.6b01911"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Ishoey, M., Chorn, S., Singh, N., Jaeger, M.G., Brand, M., Paulk, J.  (2018) Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem. Biol. <b>13<\/b>, 553\u2013560.","DOI":"10.1021\/acschembio.7b00969"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Lu, G., Surka, C., Lu, C.C., Jang, I.S., Wang, K. and Rolfe, M. (2019) Elucidating the mechanism of action of CC-90009, a novel cereblon E3 ligase modulator, in AML via genome-wide CRISPR screen. Blood <b>134<\/b> (Suppl. 1), 405.","DOI":"10.1182\/blood-2019-125492"},{"key":"73","unstructured":"73) An, J., Ponthier, C.M., Sack, R., Seebacher, J., Stadler, M.B., Donovan, K.A.  (2017) pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4<sup>CRBN<\/sup> ubiquitin ligase. Nat. Commun. <b>8<\/b>, 15398."},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Sievers, Q.L., Petzold, G., Bunker, R.D., Renneville, A., Slabicki, M., Liddicoat, B.J.  (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science <b>362<\/b>, eaat0572.","DOI":"10.1126\/science.aat0572"},{"key":"75","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","author":"P.R. Hagner","year":"2015","unstructured":"75) Hagner, P.R., Man, H.W., Fontanillo, C., Wang, M., Couto, S., Breider, M.  (2015) CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood <b>126<\/b>, 779\u2013789.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Cubillos-Zapata, C., Cordoba, R., Avendano-Ortiz, J. and Lopez-Collazo, E. (2017) Thalidomide analog CC-122 induces a refractory state in monocytes from patients with diffuse large B cell lymphoma. Leuk. Lymphoma <b>58<\/b>, 1999\u20132001.","DOI":"10.1080\/10428194.2016.1272686"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Rasco, D.W., Papadopoulos, K.P., Pourdehnad, M., Gandhi, A.K., Hagner, P.R., Li, Y.  (2019) A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies. Clin. Cancer Res. <b>25<\/b>, 90\u201398.","DOI":"10.1158\/1078-0432.CCR-18-1203"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.M., Salles, G.A., Cordoba, R.  (2020) Avadomide monotherapy in relapsed\/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. Blood <b>135<\/b>, 996\u20131007.","DOI":"10.1182\/blood.2019002395"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Matyskiela, M.E., Zhang, W., Man, H.W., Muller, G., Khambatta, G., Baculi, F.  (2018) A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J. Med. Chem. <b>61<\/b>, 535\u2013542.","DOI":"10.1021\/acs.jmedchem.6b01921"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Schafer, P.H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z.  (2018) Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: Immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann. Rheum. Dis. <b>77<\/b>, 1516\u20131523.","DOI":"10.1136\/annrheumdis-2017-212916"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Bjorklund, C.C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H.  (2020) Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia <b>34<\/b>, 1197\u20131201.","DOI":"10.1038\/s41375-019-0620-8"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A.  (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. <b>26<\/b> (Suppl. 5), v116\u2013v125.","DOI":"10.1093\/annonc\/mdv304"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Pons-Estel, G.J., Ugarte-Gil, M.F. and Alarcon, G.S. (2017) Epidemiology of systemic lupus erythematosus. Expert Rev. Clin. Immunol. <b>13<\/b>, 799\u2013814.","DOI":"10.1080\/1744666X.2017.1327352"},{"key":"84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","author":"E.S. Fischer","year":"2014","unstructured":"84) Fischer, E.S., Bohm, K., Lydeard, J.R., Yang, H., Stadler, M.B., Cavadini, S.  (2014) Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature <b>512<\/b>, 49\u201353.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Chamberlain, P.P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B.  (2014) Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. <b>21<\/b>, 803\u2013809.","DOI":"10.1038\/nsmb.2874"},{"key":"86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cell.2005.10.033","author":"T. Li","year":"2006","unstructured":"86) Li, T., Chen, X., Garbutt, K.C., Zhou, P. and Zheng, N. (2006) Structure of DDB1 in complex with a paramyxovirus V protein: Viral hijack of a propeller cluster in ubiquitin ligase. Cell <b>124<\/b>, 105\u2013117.","journal-title":"Cell","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Scrima, A., Konickova, R., Czyzewski, B.K., Kawasaki, Y., Jeffrey, P.D., Groisman, R.  (2008) Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex. Cell <b>135<\/b>, 1213\u20131223.","DOI":"10.1016\/j.cell.2008.10.045"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Sheereen, A., Alaamery, M., Bawazeer, S., Al Yafee, Y., Massadeh, S. and Eyaid, W. (2017) A missense mutation in the CRBN gene that segregates with intellectual disability and self-mutilating behaviour in a consanguineous Saudi family. J. Med. Genet. <b>54<\/b>, 236\u2013240.","DOI":"10.1136\/jmedgenet-2016-104117"},{"key":"89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","author":"G. Petzold","year":"2016","unstructured":"89) Petzold, G., Fischer, E.S. and Thoma, N.H. (2016) Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4<sup>CRBN<\/sup> ubiquitin ligase. Nature <b>532<\/b>, 127\u2013130.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Nishimura, K., Hashimoto, Y. and Iwasaki, S. (1994) (S)-form of \u03b1-methyl-N(\u03b1)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-\u03b1 production by human leukemia cell HL-60: Implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull. (Tokyo) <b>42<\/b>, 1157\u20131159.","DOI":"10.1248\/cpb.42.1157"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Mori, T., Ito, T., Liu, S., Ando, H., Sakamoto, S., Yamaguchi, Y.  (2018) Structural basis of thalidomide enantiomer binding to cereblon. Sci. Rep. <b>8<\/b>, 1294.","DOI":"10.1038\/s41598-018-19202-7"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Vargesson, N. (2009) Thalidomide-induced limb defects: Resolving a 50-year-old puzzle. Bioessays <b>31<\/b>, 1327\u20131336.","DOI":"10.1002\/bies.200900103"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Vargesson, N. (2015) Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res. C Embryo Today <b>105<\/b>, 140\u2013156.","DOI":"10.1002\/bdrc.21096"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Eichner, R., Heider, M., Fernandez-Saiz, V., van Bebber, F., Garz, A.K., Lemeer, S.  (2016) Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med. <b>22<\/b>, 735\u2013743.","DOI":"10.1038\/nm.4128"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Donovan, K.A., An, J., Nowak, R.P., Yuan, J.C., Fink, E.C., Berry, B.C.  (2018) Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife <b>7<\/b>, e38430.","DOI":"10.7554\/eLife.38430.045"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Matyskiela, M.E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K.  (2018) SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. <b>14<\/b>, 981\u2013987.","DOI":"10.1038\/s41589-018-0129-x"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Al-Baradie, R., Yamada, K., St. Hilaire, C., Chan, W.M., Andrews, C., McIntosh, N.  (2002) Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in <i>SALL4<\/i>, a new member of the SAL family. Am. J. Hum. Genet. <b>71<\/b>, 1195\u20131199.","DOI":"10.1086\/343821"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Kohlhase, J., Heinrich, M., Schubert, L., Liebers, M., Kispert, A., Laccone, F.  (2002) Okihiro syndrome is caused by <i>SALL4<\/i> mutations. Hum. Mol. Genet. <b>11<\/b>, 2979\u20132987.","DOI":"10.1093\/hmg\/11.23.2979"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Kohlhase, J. and Holmes, L.B. (2004) Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by thalidomide. Birth Defects Res. A Clin. Mol. Teratol. <b>70<\/b>, 550\u2013551.","DOI":"10.1002\/bdra.20050"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N.  (2019) p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. <b>15<\/b>, 1077\u20131084.","DOI":"10.1038\/s41589-019-0366-7"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Yang, A., Kaghad, M., Caput, D. and McKeon, F. (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. <b>18<\/b>, 90\u201395.","DOI":"10.1016\/S0168-9525(02)02595-7"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Rinne, T., Hamel, B., van Bokhoven, H. and Brunner, H.G. (2006) Pattern of <i>p63<\/i> mutations and their phenotypes\u2014Update. Am. J. Med. Genet. A <b>140<\/b>, 1396\u20131406.","DOI":"10.1002\/ajmg.a.31271"},{"key":"103","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/19531","author":"A.A. Mills","year":"1999","unstructured":"103) Mills, A.A., Zheng, B., Wang, X.J., Vogel, H., Roop, D.R. and Bradley, A. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature <b>398<\/b>, 708\u2013713.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Rouleau, M., Medawar, A., Hamon, L., Shivtiel, S., Wolchinsky, Z., Zhou, H.  (2011) TAp63 is important for cardiac differentiation of embryonic stem cells and heart development. Stem Cells <b>29<\/b>, 1672\u20131683.","DOI":"10.1002\/stem.723"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Terrinoni, A., Serra, V., Bruno, E., Strasser, A., Valente, E., Flores, E.R.  (2013) Role of p63 and the Notch pathway in cochlea development and sensorineural deafness. Proc. Natl. Acad. Sci. U.S.A. <b>110<\/b>, 7300\u20137305.","DOI":"10.1073\/pnas.1214498110"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Millimaki, B.B., Sweet, E.M., Dhason, M.S. and Riley, B.B. (2007) Zebrafish atoh1 genes: Classic proneural activity in the inner ear and regulation by Fgf and Notch. Development <b>134<\/b>, 295\u2013305.","DOI":"10.1242\/dev.02734"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Fink, E.C., McConkey, M., Adams, D.N., Haldar, S.D., Kennedy, J.A., Guirguis, A.A.  (2018) <i>Crbn<\/i><sup>I391V<\/sup> is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood <b>132<\/b>, 1535\u20131544.","DOI":"10.1182\/blood-2018-05-852798"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H.  (2018) Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc. Natl. Acad. Sci. U.S.A. <b>115<\/b>, 11802\u201311807.","DOI":"10.1073\/pnas.1814446115"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M. and Deshaies, R.J. (2001) Protacs: Chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U.S.A. <b>98<\/b>, 8554\u20138559.","DOI":"10.1073\/pnas.141230798"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S.  (2015) Phthalimide conjugation as a strategy for in vivo target protein degradation. Science <b>348<\/b>, 1376\u20131381.","DOI":"10.1126\/science.aab1433"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E.  (2016) Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. <b>55<\/b>, 807\u2013810.","DOI":"10.1002\/anie.201507634"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Robb, C.M., Contreras, J.I., Kour, S., Taylor, M.A., Abid, M., Sonawane, Y.A.  (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. (Camb.) <b>53<\/b>, 7577\u20137580.","DOI":"10.1039\/C7CC03879H"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Olson, C.M., Jiang, B., Erb, M.A., Liang, Y., Doctor, Z.M., Zhang, Z.  (2018) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. <b>14<\/b>, 163\u2013170.","DOI":"10.1038\/nchembio.2538"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D.  (2018) Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J. Med. Chem. <b>61<\/b>, 482\u2013491.","DOI":"10.1021\/acs.jmedchem.6b01872"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) de Wispelaere, M., Du, G., Donovan, K.A., Zhang, T., Eleuteri, N.A., Yuan, J.C.  (2019) Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. <b>10<\/b>, 3468.","DOI":"10.1038\/s41467-019-11429-w"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Silva, M.C., Ferguson, F.M., Cai, Q., Donovan, K.A., Nandi, G., Patnaik, D.  (2019) Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife <b>8<\/b>, e45457.","DOI":"10.7554\/eLife.45457.037"},{"key":"117","unstructured":"117) Zeng, M., Xiong, Y., Safaee, N., Nowak, R.P., Donovan, K.A., Yuan, C.J.  (2020) Exploring targeted degradation strategy for oncogenic KRAS(G12C). Cell Chem. Biol. <b>27<\/b>, 19\u201331.e16."},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Chamberlain, P.P., D\u2019Agostino, L.A., Ellis, J.M., Hansen, J.D., Matyskiela, M.E., McDonald, J.J.  (2019) Evolution of cereblon-mediated protein degradation as a therapeutic modality. ACS Med. Chem. Lett. <b>10<\/b>, 1592\u20131602.","DOI":"10.1021\/acsmedchemlett.9b00425"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Krumm, A., Hickey, L.B. and Groudine, M. (1995) Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes Dev. <b>9<\/b>, 559\u2013572.","DOI":"10.1101\/gad.9.5.559"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Adelman, K. and Lis, J.T. (2012) Promoter-proximal pausing of RNA polymerase II: Emerging roles in metazoans. Nat. Rev. Genet. <b>13<\/b>, 720\u2013731.","DOI":"10.1038\/nrg3293"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S.  (1998) DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev. <b>12<\/b>, 343\u2013356.","DOI":"10.1101\/gad.12.3.343"},{"key":"122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0092-8674(00)80713-8","author":"Y. Yamaguchi","year":"1999","unstructured":"122) Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S.  (1999) NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell <b>97<\/b>, 41\u201351.","journal-title":"Cell","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Marshall, N.F. and Price, D.H. (1995) Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem. <b>270<\/b>, 12335\u201312338.","DOI":"10.1074\/jbc.270.21.12335"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Yamada, T., Yamaguchi, Y., Inukai, N., Okamoto, S., Mura, T. and Handa, H. (2006) P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol. Cell <b>21<\/b>, 227\u2013237.","DOI":"10.1016\/j.molcel.2005.11.024"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Patel, M.C., Debrosse, M., Smith, M., Dey, A., Huynh, W., Sarai, N.  (2013) BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF\/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell. Biol. <b>33<\/b>, 2497\u20132507.","DOI":"10.1128\/MCB.01180-12"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Winter, G.E., Mayer, A., Buckley, D.L., Erb, M.A., Roderick, J.E., Vittori, S.  (2017) BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell <b>67<\/b>, 5\u201318.e19.","DOI":"10.1016\/j.molcel.2017.06.004"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S.  (2018) UBE2G1 governs the destruction of cereblon neomorphic substrates. Elife <b>7<\/b>, e40958.","DOI":"10.7554\/eLife.40958"},{"key":"128","doi-asserted-by":"publisher","unstructured":"128) Sievers, Q.L., Gasser, J.A., Cowley, G.S., Fischer, E.S. and Ebert, B.L. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4<sup>CRBN<\/sup> activity. Blood <b>132<\/b>, 1293\u20131303.","DOI":"10.1182\/blood-2018-01-821769"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Hartmann, M.D., Boichenko, I., Coles, M., Zanini, F., Lupas, A.N. and Hernandez Alvarez, B. (2014) Thalidomide mimics uridine binding to an aromatic cage in cereblon. J. Struct. Biol. <b>188<\/b>, 225\u2013232.","DOI":"10.1016\/j.jsb.2014.10.010"},{"key":"130","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1021\/acsomega.8b00959","author":"I. Boichenko","year":"2018","unstructured":"130) Boichenko, I., Bar, K., Deiss, S., Heim, C., Albrecht, R., Lupas, A.N.  (2018) Chemical ligand space of cereblon. ACS Omega <b>3<\/b>, 11163\u201311171.","journal-title":"ACS Omega","ISSN":"https:\/\/id.crossref.org\/issn\/2470-1343","issn-type":"print"}],"container-title":["Proceedings of the Japan Academy, Series B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/96\/6\/96_PJA9606B-01\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T03:35:26Z","timestamp":1592019326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/96\/6\/96_PJA9606B-01\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2183\/pjab.96.016","relation":{},"ISSN":["0386-2208","1349-2896"],"issn-type":[{"value":"0386-2208","type":"print"},{"value":"1349-2896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}